Retatrutide research explained: what the published human study shows
Retatrutide (LY3437943, sometimes shortened to RTA) is an investigational molecule studied as an agonist at GIP, GLP-1 and glucagon receptors. The 48-week phase 2 obesity trial is the peer-reviewed human study discussed here; Lilly also reported phase 3 TRIUMPH topline results in 2026, which are company announcements rather than peer-reviewed papers. Lilly still describes retatrutide as investigational. A laboratory research product is not trial material.
Published: · Last reviewed:
Retatrutide products offered for laboratory research are research materials only, not medicines or clinical-trial supplies. They are not for human or veterinary use, ingestion, injection, diagnosis, treatment, or self-experimentation. Research materials only. Not for human or veterinary use.
Related research reading
What “retatrutide” refers to in research
The name identifies Eli Lilly’s investigational molecule LY3437943 in the cited publication and trial registry. The paper reports a randomized, placebo-controlled phase 2 study in adults with obesity or overweight plus a weight-related condition. It describes research carried out under a clinical protocol; a product sold for laboratory research is not the study drug, a prescription, or evidence of equivalent identity, quality, or performance.
What phase 2 measured—and what it cannot settle
Over 48 weeks, the phase 2 trial measured body-weight change and safety in enrolled participants. Its 12 mg group had a reported least-squares mean weight change of −24.2%, versus −2.1% with placebo; gastrointestinal events were common and dose-related. These are results for that trial population and protocol, not a treatment promise, proof of long-term outcomes, or a head-to-head demonstration of superiority. Larger and longer studies are needed to answer remaining questions.
Later phase 3 announcements and current status
Lilly announced topline results from TRIUMPH-1 in May 2026 and TRIUMPH-2 and TRIUMPH-3 in July 2026. These are manufacturer-reported topline announcements; Lilly says detailed TRIUMPH-2 and TRIUMPH-3 results are intended for future presentation and peer-reviewed publication. They should not be presented as peer-reviewed findings. Lilly’s July 2026 explainer still calls retatrutide investigational and not approved by any regulatory agency; the FDA likewise says it has not been found safe and effective for any condition. The EMA record cited here is a paediatric-investigation-plan decision, not a marketing authorisation. These dated statements do not replace checking current regulator records. Manufacturer status update (July 2026; not a regulator): https://www.lilly.com/news/stories/what-to-know-about-retatrutide. Original company topline announcements (not peer-reviewed): TRIUMPH-1, 21 May 2026: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss; TRIUMPH-2 and TRIUMPH-3, 23 July 2026: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional.
Research references
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — The New England Journal of Medicine, doi:10.1056/NEJMoa2301972
- A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (NCT04881760) — ClinicalTrials.gov, U.S. National Library of Medicine, NCT04881760
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — U.S. Food and Drug Administration, FDA drug alert; accessed 24 September 2026
- EMEA-003258-PIP02-23 – paediatric investigation plan — European Medicines Agency, EMA decision P/0336/2024; EMA/414227/2024
- TRIUMPH-1 preliminary Phase 3 topline results (manufacturer announcement; not peer-reviewed) — Eli Lilly and Company, Manufacturer press release, 21 May 2026
- TRIUMPH-2 and TRIUMPH-3 preliminary Phase 3 topline results (manufacturer announcement; not peer-reviewed) — Eli Lilly and Company, Manufacturer press release, 23 July 2026
Reference questions
Is retatrutide an approved medicine?
As of Lilly’s July 2026 explainer, the company describes retatrutide as investigational and not approved by any regulatory agency; the FDA also says it has not been found safe and effective for any condition. The phase 3 topline announcements do not themselves constitute approval. Check the competent regulator for current status in your jurisdiction.
Does phase 2 prove a treatment benefit for an individual?
No. Group-level outcomes from one clinical trial cannot predict an individual result or establish a personal treatment choice. This is research information, not medical advice.